Pr. Christophe Massard: Chairman of the SAB, Gustave Roussy, France

Medical oncologist, Head of Department DITEP between Sep 2017 and June 2021 and back in 2024. Principal investigators of 50 phase I trials, 1 phase II trial (prostate cancer), and co-investigator of more than 80 clinical trials (phase 1 trials and GU cancers).Focus on new drugs, GU cancer and translational research aspects related to precision medicine (MOSCATO, MATCH-R). Pr Massard has contributed to over 100 peer-reviewed publications, including publications in European Urology, Annals of Oncology and Journal of Clinical Oncology.

Pr. Susan Bates

Dr. Susan Bates received her M.D. degree from the University of Arkansas School of Medicine. She completed her clinical training in internal medicine at Georgetown University in Washington, D.C., and in medical oncology at the National Cancer Institute (NCI) in Bethesda, MD. Dr. Bates was a Lead Clinical Investigator and Head of the Molecular Therapeutics Section in the Developmental Therapeutics Branch of the Center for Cancer Research before moving to Columbia University in August 2015.

During her years at the NCI, Dr. Bates led a highly successful translational research program focused on mechanisms of multidrug resistance and approaches to evaluate and improve the activity of epigenetic modifying agents. Her laboratory was among the first to clone the multidrug transporter ABCG2, eventually characterizing its function and its role in chemo-resistance and chemo-protection. This effort built upon earlier work elaborating the role of the multi-drug transporter P-glycoprotein that had defined the drug sensitivity profiles of cell lines in vitro, particularly in the NCI-60 cell line panel. The latter observation continues to impact how the NCI-60 cell line panel is used in drug discovery, and helped her identify a novel agent, at that time known as depsipeptide. Dr. Bates brought this drug to the clinic and after completing its phase I testing, served as Principal Investigator of a multi-institutional, international Phase II study of romidepsin (depsipeptide) in cutaneous and peripheral T-cell lymphoma. Working with Gloucester Pharmaceuticals, the data from this study were included in New Drug Applications (NDA) to the U.S. Food & Drug Administration (FDA). This partnership led to approval by the FDA of romidepsin for two indications - initially for cutaneous T-cell lymphoma and later for peripheral T-cell lymphoma.

Dr. Bates' current interests are both laboratory and clinical in nature. Her laboratory efforts include laboratory and translational studies on drug resistance in T-cell lymphomas and advanced solid tumors including breast, pancreatic, neuroendocrine, renal and lung cancers. Her work is dedicated to new drug development, and finding antineoplastic agents that, alone or in combination with other anticancer agents, improve the options available for difficult to treat cancers. Emanating from the clinical and translational development of romidepsin, a histone deacetylase (HDAC) inhibitor, a current focus is on epigenetic therapies, and the development of combination therapies to use with HDAC inhibitors in refractory advanced cancers, including solid tumors. She also has a special interest in drug delivery and drug distribution and the role of the blood brain barrier in creating a sanctuary site for cancers that metastasize to the brain. Clinically, her goal has always been to translate ideas from the laboratory to clinical trials, an effort that has proven very successful. Clinically she seeks to develop combination therapies with histone deacetylase inhibitors for the therapy of solid tumors; and to develop therapies to treat central nervous system metastases, a complication of cancer that is becoming a greater problem as patients live longer with cancer.

Pr. Patricia LoRusso :

As the associate director of experimental therapeutics at Yale Cancer Center, Dr. LoRusso is a nationally recognized expert in developing new cancer drugs through clinical trials. Dr. LoRusso has pioneered significant advances in medical oncology, drug development, and early phase clinical trials for her work at Wayne State University’s Barbara Karmanos Cancer Institute as director of both the phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Dr. LoRusso joined the AACR in 1988, served on the AACR Board of Directors from 2015 to 2018, and received the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research in 2022. In 2023, she was inducted as a Fellow of the AACR Academy. She currently serves with distinction as chair of the AACR Exploratory IND/Biomarker-Driven Clinical Trials Task Force; chair of the AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research Award Committee; and cochair of the AACR Precision Combination Therapy Task Force. She has been a member of the AACR Project GENIE External Advisory Board since its inception in 2015.

Dr. LoRusso’s extensive involvement with the AACR has also included serving as a member of the AACR Cancer Disparities Progress Report Steering Committee (2022); member, AACR Education and Training Committee (2019-2022); member, AACR Nominating Committee (2019-2021); chair (2019-2020) and member (2018-2019), AACR Satellite Educational Symposia Committee; member, AACR June L. Biedler Prize for Cancer Journalism Judging Panel (2017-2020); member, AACR Continuing Medical Education Committee (2012-2014, 2017-2020); vice chair (2018-2019) and cochair (2013-2014, 2016-2017), AACR Annual Meeting Program Committee; member, AACR Science Policy and Government Affairs Committee (2016-2019); codirector (2016-2018) and faculty member (2004, 2005, 2009-2012), AACR/ASCO Methods in Clinical Cancer Research Workshop; faculty member, AACR Educational Workshop, “Australia and Asia Pacific Clinical Oncology Research Development” (2012, 2014, 2016, 2018); member, AACR Cancer Progress Report Steering Committee (2017); chair (2016-2017) and member (2012-2015), AACR Women in Cancer Research Council; chair, AACR Team Science Award Committee (2016-2017); cochair, AACR Annual Meeting Clinical Trials Committee (2012-2015); member, AACR Annual Meeting Exhibits Committee (2012-2014); member, AACR Clinical Research and Experimental Therapeutics Awards Selection Committee (2007-2009, 2012-2014); member, AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research Committee (2007-2009); member, AACR-Richard and Hinda Rosenthal Foundation Award Committee (2007-2009); member, Scientific Review Committee, Second Annual International Conference on Molecular Diagnostics in Cancer Therapeutic Development (2007); member, AACR-Women in Cancer Research Charlotte Friend Lectureship Committee (2006); and member, Scientific Program Committee, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2003-2005).

Dr. LoRusso served on the editorial boards of the AACR journals Molecular Cancer Therapeutics (2012-2015) and Clinical Cancer Research (2011-2014). She was also coleader of the Stand Up To Cancer (SU2C)-Melanoma Research Alliance (MRA) Melanoma Dream Team. The AACR serves as the Scientific Partner of Stand Up To Cancer.

Throughout her career, Dr. LoRusso has received numerous honors and awards, including the World Affairs Council of Connecticut Luminary Award (2018); National Organization of Italian-American Women “Three Wise Women” honoree (2017); Massachusetts General Hospital Cancer Center the one hundred honoree (2014); ESMO Targeted Anticancer Therapies (TAT) Honorary Award (2014); Michigan State University Distinguished Alumni Award (2014); Karmanos Cancer Institute Faculty Award for Clinical Excellence (2013); American College of Osteopathic Internists Researcher of the Year Award (2010); National Cancer Institute Michaele Christian Oncology Development Award (2008); Crain’s Detroit Business Heroes of Healthcare Award (2008); Marygrove College Distinguished Alumni Award (2008); Top Doctors honoree (2007, 2009, 2011-2013, 2018); and the Michigan Society for Medical Research Bennett J. Cohen Educational Leadership Award for Medical Research (2004). Dr. LoRusso received an honorary PhD from Michigan State University in 2015 and was elected as a fellow of the American Society of Clinical Oncology in 2022.

Dr. LoRusso received her BS from Marygrove College and her DO from Michigan State University. Prior to her appointment at the Yale School of Medicine, she served in numerous leadership roles at Wayne State University’s Barbara Ann Karmanos Cancer Institute, including as director of the Phase I Clinical Trials Program and director of the Eisenberg Center for Translational Therapeutics.

Pr. Udai Banergy

Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance.

He is a key member of the Cancer Therapeutics Unit, providing early clinical insights into areas of unmet need and clinical relevance during target prioritisation. He leads the Clinical Pharmacodynamics Biomarker Group, which plays a crucial role in transferring pharmacodynamic biomarkers used in drug discovery on to platforms that can be used in clinical trials. 

Professor Banerji is the Deputy Director of the Drug Development Unit which straddles The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust. He leads academic studies sponsored by the ICR and Cancer Research UK and trials sponsored by pharmaceutical companies.

He is a passionate advocate of the Pharmacological Audit Trial and focuses on hypothesis testing, biomarker-enriched first-in-human clinical trials crucial in making go-no-go decisions in early phase clinical trials and accelerating the development of active anticancer drugs.

As well as working to optimise the dose, schedules and predictive biomarkers, he also runs the Clinical Pharmacology Adaptive Therapy Group which focuses on translational proteomic approaches to study drug resistance and methods of overcoming resistance using a combination therapies in clinical trials. 

Professor Banerji has multiple collaborations within the ICR, including the pharmacological effects on evolution (Dr Andrea Sottoriva), the use of proteomics to study drug resistance (Dr Jyoti Choudhary and Dr Paul Huang), the use of PET and MRS as pharmacodynamic biomarkers (Professor Wim Oyen and Professor Martin Leach) and exploiting the use of ultrasound in cancer therapy (Professor Jeff Bamber and Professor Gail Ter Haar).

On completion of his training in basic medicine (MBBS) at the University of Calicut, India, in 1991 and in internal medicine (MD, DNB) at the University of Bombay in 1994, Professor Banerji moved to the UK to work in oncology, qualifying in internal medicine (MRCP) in 2000. 

He joined the ICR in 2000 as a clinical fellow as part of their PhD programme and was awarded his PhD (University of London) in 2005. He started his training in medical oncology at The Royal Marsden in 2003 and was awarded his Certificate of Completion of Training in Medical Oncology in 2007. He joined the ICR as a Career Development Faculty and an honorary consultant at The Royal Marsden in 2007. 

In 2012, he was confirmed as Faculty of the ICR and was awarded his Fellowship of the Royal College of Physicians (FRCP). He was confirmed as a Cancer Research UK Reader in 2013 and as an NIHR Professor of Molecular Cancer Pharmacology in 2018. 

As a phase I physician, he has led the clinical development of first-in-human studies of a range of anticancer drugs developed at the ICR, including: luminespib (HSP90 inhibitor); CHR-3996 (HDAC inhibitor); AT13148 (ROCKI/II inhibitor); AZD5363 (AKT inhibitor); BAL3833 (pan-RAF inhibitor); ONX-0801 (alpha folate targeted TS inhibitor); SRA737 (CHK1 inhibitor) and BOS722 (MPS1 inhibitor). He has been a principal investigator and a sub-investigator in over 35 and 100 first-in-human studies, respectively. 

In addition to being responsible for the clinical management of patients he has been involved in the pharmacodynamic biomarker development of many of these drugs as the head of the Clinical Pharmacodynamics Biomarker Group. He works closely with Dr Florence Raynaud in the Drug Metabolism Pharmacokinetic (DMPK) Group to interpret and use pharmacokinetic data and study pharmacokinetic-pharmacodynamic models. 

He runs pharmaceutically sponsored studies and is also passionate about investigator-initiated clinical trials sponsored by the ICR, as well as charities, such as Cancer Research UK. A number of these investigator-initiated studies have been the basis of further evaluation of these drugs by other academic routes such as the National Institute for Health Research (NIHR).

His focus on the re-wiring of signal transduction as a mechanism of drug resistance and its use in designing clinical trials led to the award of a 5-year NIHR Research Professorship in 2017. It has also led to the development of clinical protocols evaluating combinations therapy (TAX-TORC and FRAME studies) run through the national Experimental Cancer Medicine Centre (ECMC) networks.

Professor Banerji was part of the ICR group awarded the AACR Team Science award in 2012 and the Cancer Research UK Translational Research award in 2013.

Dr. Jean-Yves Bizzari

Jean-Pierre Bizzari, MD, is a Doctor of Medicine, graduate of the Nice medical school and a specialist in oncology. He served as Executive Vice-President, Group Head, and Clinical Oncology Development (US, Europe, and Asia/Japan) at Celgene from 2008 to 2015. Prior to joining Celgene, he served as Vice President for Clinical Development Oncology at Sanofi-Aventis, based in the US, from 2004 to 2008. Between 1993 and 2004 he held the same position successively at Rhône-Poulenc Rorer, Aventis and Sanofi-Synthélabo, also in the US. Jean-Pierre Bizzari, MD, was previously head of the oncology department at Servier, after working as an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Since 2005 he has been a member of the international scientific committee of the French National Cancer Research Institute.

Pr. Jean-Yves Blay:

Jean-Yves Blay, Ph.D. has held the post of General Director of the Centre Léon Bérard in Lyon, France, since 2014 and renewed in 2019. He became President of Unicancer in 2019. He is President of the French Sarcoma Group and Director of the European Reference Network for Rare Adult Cancers (EURACAN). He is also Network Director of LYRICAN +.

Between 2009 and 2012 he held the position of President of the European  Organisation for Research and Treatment of Cancer (EORTC). Prof. Blay currently holds various other university and hospital positions. He is a member of the European Union Committee of Experts of Rare Disease, the European Commission’s Scientific Panel for Health (SPH) and served as a Faculty Coordinator for Sarcoma for the European Society of Medical Oncology (ESMO) between 2012 and 2016 and has been named Director of Public Policy from January 2023.

Trained as a medical oncologist with a PhD from the University Claude Bernard in Lyon (France), his research activities have been focused on the role of immune effector cells and cytokines in cancer. Prof. Blay is a member of various scientific societies and academic expert groups, has been awarded several honors and is the author of more than 200 publications over the last three years.

Pr. Jean-Yves Douillard

In a career spanning more than 30 years, Prof Douillard has achieved international recognition as a leading expert in lung cancer and gastrointestinal oncology, holding a number of leadership positions.

At the University of Nantes, he was Professor in Medical Oncology, while at the Integrated Centers of Oncology (ICO) Rene Gauducheau, also in Nantes, he was Head of the Medical Oncology Department and later Director of Clinical and Translational Research. In addition, he spent a total of four years working in the US, initially at the National Cancer Institute and later at the Center for Drug Evaluation and Research, part of the Food and Drug Administration (FDA). He received his PhD in 1993.

Throughout his career, Prof Douillard has led clinical trials in relation to lung cancer and GI tumours and investigated targeted therapies, publishing his work in leading scientific journals. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.

ESMO President Fortunato Ciardiello, said: “This is an important appointment which reflects the growing role and remit of ESMO. As we expand our horizons beyond Europe to continue meeting the needs of our members and cancer patients across the world, we must also expand our scientific and educational initiatives, while maintaining the highest possible standards.”

He continued: “The Chief Medical Officer has a critical role to play by incorporating the latest advances in medical oncology and best practice methodologies into all of our scientific activities – from Clinical Practice Guidelines to the development of scientific congress programmes.

Dr. Jabbour,

joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML. This research has also provided insight into the biology of leukemias. He has extensively addressed the question of resistance to tyrosine kinase inhibitors and to analyze the outcome of these patients. We have identified different mechanisms of resistance and described the clinical significance of them. This has clinical significance in establishing new milestones and leading to personalized therapy. This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients at risk and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analog clofarabine. This may change the standard of care for the management of patients with AML. Furthermore, I am currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.

Pr. Ignacio Melero

Graduated (1988) in Medicine from the University of Navarra and a Ph.D. (1994), with an extraordinary doctorate award, from the Autonomous University of Madrid. He specialized in Immunology at the Hospital Universitario de la Princesa (Madrid, 1993). He worked for four years in the research center of the company Bristol Myers-Squib in Seattle (USA).

At Clinica Universidad de Navarra:

• Co-director of the Immunology and Immunotherapy Service since 2015
• Senior researcher at the Center for Applied Medical Research (CIMA).
• Professor of Immunology.

Pr. Josep Tabernero

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain, and he is currently Head of the Medical Oncology Department at the Vall d’Hebron University Hospital, Director of the Vall d’Hebron Institute of Oncology (VHIO) and Professor of Medicine at UVic-UCC. He has been Principal Investigator of several Phase I pharmacodynamic studies and translational projects with tumor-directed targeted therapies and immune-based therapies.

His research aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery, Clinical Cancer Research, Cancer Treatment Reviews, and Nature Reviews Clinical Oncology. He has (co) authored approximately 500 peer-reviewed papers with an H-Index of 115.

He was the President (2018 – 2019) of the European Society for Medical Oncology´s (ESMO), and also serves on its Public Policy as well as Cancer Medicines Committees. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO). He has also been a member of the Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, TAT and WCGIC meetings

Pr. Timothy Yap:

Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is a Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department ofThoracic/Head and Neck Medical Oncology. Dr. Yap is Vice President and Head of Clinical Development in the Therapeutics Discovery Division, a drug discovery biopharmaceutical division where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Khalifa Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes.    Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR, PARP1, WEE1, POLQ, USP1, PKMYT1, PARG, CHK1, ATM and DNA-PK inhibitors, next generation CDK2, CDK4 and CDK7-selective inhibitors, YAP/TEAD inhibitors, Werner helicase inhibitors, SMARCA2 degraders, as well as the development of novel immunotherapeutics.   Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.   Dr. Yap gained his BSc degree with First Class Honors in Immunology and Infectious Diseases at Imperial College London, UK, and was awarded the Huggett Memorial Prize. His BSc laboratory research involved an immunogenetics study into the human T-cell lymphotropic virus under the supervision of Professor Charles Bangham. He subsequently went on to attain his Medical degree from Imperial College London, UK, before completing general medical training in Oxford.   Dr. Yap undertook a Clinical Fellowship in the Phase I Drug Development Unit at the Royal Marsden Hospital with Professors Stan Kaye and Johann de Bono, before completing a PhD in Molecular Pharmacology in the Division of Cancer Therapeutics at The Institute of Cancer Research with Professors Michelle Garrett and Paul Workman under a Cancer Research UK Fellowship. His PhD laboratory research focused on the preclinical and clinical development of AKT inhibitors, and associated predictive and pharmacodynamic biomarkers. Dr. Yap completed his specialist training in medical oncology at the Royal Marsden Hospital and was awarded a National Institute for Health Research (NIHR) Academic Clinical Lectureship in Medical Oncology. He was subsequently appointed as Consultant Medical Oncologist and NIHR Biomedical Research Centre Clinician Scientist jointly in the Phase I Drug Development Unit, Lung Cancer Unit and Cancer Biomarkers Laboratory at the Royal Marsden Hospital and The Institute of Cancer Research in London, UK.   Dr. Yap is and/or has been Principal Investigator for multiple clinical trials and translational studies evaluating novel strategies for targeting the DNA damage response in cancer, such as PARP1/2, ATR, PARP1-selective, WEE1, POLQ, USP1, PKMYT1, PARG, CHK1, ATM and DNA-PK inhibitors, as well as agents against other synthetic lethal targets such as Werner helicase and SMARC2. He also leads early phase trials and translational studies of next generation CDK4 and CDK2-selective inhibitors, YAP/TEAD inhibitors, metabolic targets including Glutaminase and OXPHOS, epigenetic targets such as EZH2 and BET, and key signaling pathways, with a focus on the PI3K/AKT pathway. Dr. Yap is currently Principal Investigator of four NCI CTEP trials of novel combination therapies involving innovative biomarker-driven approaches across the NCI Experimental Therapeutics Clinical Trials Network. He was Lead Investigator for the AKT inhibitor arm of the UK National Lung Matrix Trial, which was one of the largest precision medicine trials in any cancer globally. Dr. Yap leads immuno-oncology clinical and associated translational studies, including novel agents targeting PD-1/PD-L1, ICOS, IDO, LAG3, TIM3, STING, TGFbeta, adenosine A2A receptor and fucosylation. He was previously the UK Chief Investigator for the CheckMate 331 Phase III trial in relapsed small cell lung cancer and the KEYNOTE-158 Phase II biomarker study in advanced solid tumors and multiple novel immunotherapy combination phase I trials.   His laboratory interests include the translational analysis of patient tumors and circulating tumor DNA as predictive biomarkers of response and resistance for novel agents in clinical trials and the development of pharmacodynamic biomarkers. Dr. Yap is PI of active peer reviewed federal grants, including a NIH/NCI R01, two Department of Defense (DOD) grants, a V Foundation Scholar grant, a Golfers against Cancer grant and a SINF grant, as well as previous grants from the British Lung Foundation, Academy of Medical Sciences and US Prostate Cancer Foundation.   Dr. Yap was the recipient of the 2019 NCI Michaele C. Christian Oncology Development Award, the 2020 V Foundation Scholar Award, the 2021 Irwin H. Krakoff Award for excellence in clinical research, and was a Honoree for President’s Recognition of Faculty Excellence at MD Anderson in 2021. He previously received the McElwain Prize in Medical Oncology from the UK Association of Cancer Physicians and a Young Investigator Award from the Prostate Cancer Foundation. He has also received five ASCO Foundation merit awards, the AACR-AstraZeneca International Scholar Award, AACR-Pezcoller Foundation Scholar Award, as well as awards from the EORTC and ETOP.    Dr. Yap has published more than two hundred articles in peer-reviewed journals, including the New England Journal of Medicine, Nature, Nature Medicine, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Cancer Cell, Science Translational Medicine, Nature Reviews Cancer and Nature Reviews Clinical Oncology, as well as multiple book chapters. He has edited two books on the development of early phase clinical trials and on targeting the DNA Damage Response. Dr. Yap is a Scientific Editor of Cancer Discovery, and Associate Editor of the British Journal of Cancer and the Journal of Hematology & Oncology.    Dr. Yap was previously Co-Chair of the Clinical Trials Committee at the AACR Annual Meeting, Co-Chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and Chair of the AACR Industry Roundtable meeting. He has served on the Scientific Program Committees of the ASCO, AACR, AACR-NCI-EORTC, ESMO, ESMO TAT, ESMO MAP and ESMO Asia Annual Conferences.   He is a member of the AACR Precision Combination Therapy Task Force and was previously a member of the ESMO OncologyPRO Working Group, the UK NCRI Lung Cancer Clinical Studies Group, the EORTC Lung Cancer Group and the EAPM Sub-Committee on Clinical Trials Framework. Dr. Yap previously served as co-leader of the Molecular Biology Module on The Institute of Cancer Research MSc Oncology Course and was a founding member of the UK ECMC Junior Investigator Network Group.    Dr. Yap is is currently Faculty on the EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research, having previously served on the Faculty of the ASCO/AACR Methods in Clinical Cancer Research Workshop in Vail. He currently serves on the MD Anderson Academic Mentoring council and is a Program Lead of the Leading Clinical Research Faculty Learning Series.